Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Researchers discover cancer-killing properties of frankincense in ovarian cancer

Researchers from the University of Leicester have, for the first time, demonstrated the potential of treating ovarian cancer using the Christmas gift frankincense.

20 Dec 2013

TGen, Nemucore, and Barrow collaboration aims for new drugs to treat glioblastoma

The Ben & Catherine Ivy Foundation today announced a $3 million grant to the Translational Genomics Research Institute (TGen), Nemucore Medical Innovations Inc., and Barrow Neurological Institute at St. Joseph's Hospital and Medical Center to help fund significant brain tumor research in Arizona.

18 Dec 2013

Scientists back ovarian cancer preventative surgery to improve survival

A study by Manchester scientists backs preventative surgery to improve survival for women who are at greater risk of getting ovarian cancer and suggests it appears helpful for women at risk of getting breast cancer because of genetic faults.

18 Dec 2013

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

Atara Biotherapeutics, Inc., a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced today that it has secured $38.5 million in initial closings under its Series B financing. In this round, investors Amgen Ventures, Celgene Corporation, and EcoR1 Capital, joined existing investors Alexandria Venture Investments, DAG Ventures, Domain Associates, and Kleiner Perkins Caufield & Byers.

17 Dec 2013

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

VG Life Sciences, a biotechnology company, announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors.

13 Dec 2013

More outreach needed for family members who carry genetic risks of cancer

A study done by researchers at Fox Chase Cancer Center shows that many relatives of patients who undergo testing for a gene linked to breast and ovarian cancers misinterpret the results, and less than half of those who could benefit from genetic testing say they plan to get tested themselves-despite the fact that knowing your genetic status may help catch the disease in its earliest stages.

13 Dec 2013

Immunocellular Therapeutics reports positive results from ICT-107 Phase II study in glioblastoma patients

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") announced that ICT-107, its dendritic cell-based vaccine, demonstrated a statistically significant increase in progression-free survival (PFS) in patients with newly diagnosed glioblastoma multiforme (GBM) in its randomized, placebo-controlled phase II trial.

12 Dec 2013

Report: Screen all endometrial cancer patients for Lynch syndrome

A recent article by Norris Cotton Cancer Center researchers published in the January 2014 issue of the journal Clinical Chemistry reviews the scientific evidence that warrants screening all endometrial cancers for Lynch syndrome. Next to colorectal cancer, endometrial cancer is the most common form of cancer in women with Lynch syndrome.

12 Dec 2013

Researchers identify 10 genes that may signify trifecta of benefits for women with ovarian cancer

Researchers in the Women's Cancer Program at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute have identified a series of 10 genes that may signify a trifecta of benefits for women diagnosed with ovarian cancer and ultimately reflect improved survival outcomes.

10 Dec 2013

New drug delivery system successfully treats advanced-stage ovarian cancer in mice

Scientists at Rutgers University have developed a targeted drug delivery system that they believe could make ovarian cancer more treatable and increase survival rates for the most deadly gynecological cancer in the United States.

9 Dec 2013

Adocia gets development and commercialization rights in nanotechnology for drug delivery

Adocia, a biotechnology company specializing in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, announces today the signature of an exclusive license agreement with the CNRS, the University Bordeaux I, the Institut Polytechnique de Bordeaux and Aquitaine Science Transfert.

9 Dec 2013

Novel device may simplify monitoring of patients' response to treatment for ovarian cancer

A microchip-based device developed by Massachusetts General Hospital investigators may greatly simplify the monitoring of patients' response to treatment for ovarian cancer - the most lethal form of gynecologic cancer - and certain other malignancies.

6 Dec 2013

Archimedes Model simulation suggests genetic screening for breast cancer risk can reduce deaths

Archimedes Inc., a healthcare modeling and analytics company, today announced results of a simulated clinical trial which found that the seven single-nucleotide polymorphisms (7SNP) genetic test for breast cancer was most cost effective when used to guide MRI screenings for patients found to have an intermediate lifetime risk of developing the disease.

5 Dec 2013

New method for counting tumor-fighting cells to predict ovarian cancer

One way to predict survival of many types of cancer is by counting the number of tumor-attacking immune cells that have migrated into the tumor in an effort to eradicate it - a sign of the body's immune response to the cancer. However, quantifying these armies of immune cells has been difficult - until now.

5 Dec 2013

Women who test negative for family-specific BRCA2 mutations may have four times risk for breast cancer

Women who are members of families with BRCA2 mutations but who test negative for the family-specific BRCA2 mutations are still at greater risk for developing breast cancer compared with women in the general population, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

27 Nov 2013

SillaJen executes definitive merger agreement to acquire Jennerex

SillaJen, Inc., a privately-held biotherapeutics and contract research company focused on the development of targeted biological products for cancer, announced today that it had executed a definitive merger agreement to acquire San Francisco-based Jennerex, Inc.

26 Nov 2013

Super cocktail of six natural compounds killed 100% of breast cancer cells without toxic side effects

A study led by Madhwa Raj, PhD, Research Professor in Obstetrics and Gynecology at LSU Health Sciences Center New Orleans and its Stanley S. Scott Cancer Center, has found that a super cocktail of six natural compounds in vegetables, fruits, spices and plant roots killed 100% of sample breast cancer cells without toxic side effects on normal cells.

25 Nov 2013

Probe to measure immune function could lead to determine nanoparticle-based drugs for cancer patients

The development of a probe to measure the body's immune function could lead to more accurate, individualized doses for cancer patients prescribed nanoparticle-based drugs, according to research conducted at the University of North Carolina.

21 Nov 2013

DNA-damaging drug and MK2 inhibitor combination could be effective against cancer

About half of all cancer patients have a mutation in a gene called p53, which allows tumors to survive and continue growing even after chemotherapy severely damages their DNA.

20 Nov 2013

ESBC joins with Athena Breast Health Network to advance personalized breast cancer risk assessment

Edith Sanford Breast Cancer (ESBC), part of the Sanford Health system based in Sioux Falls, SD, today announced it is partnering with the Athena Breast Health Network, a University of California program, to advance the use of a personalized breast cancer risk assessment.

16 Nov 2013

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Researchers discover cancer-killing properties of frankincense in ovarian cancer

TGen, Nemucore, and Barrow collaboration aims for new drugs to treat glioblastoma

Scientists back ovarian cancer preventative surgery to improve survival

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

More outreach needed for family members who carry genetic risks of cancer

Immunocellular Therapeutics reports positive results from ICT-107 Phase II study in glioblastoma patients

Report: Screen all endometrial cancer patients for Lynch syndrome

Researchers identify 10 genes that may signify trifecta of benefits for women with ovarian cancer

New drug delivery system successfully treats advanced-stage ovarian cancer in mice

Adocia gets development and commercialization rights in nanotechnology for drug delivery

Novel device may simplify monitoring of patients' response to treatment for ovarian cancer

Archimedes Model simulation suggests genetic screening for breast cancer risk can reduce deaths

New method for counting tumor-fighting cells to predict ovarian cancer

Women who test negative for family-specific BRCA2 mutations may have four times risk for breast cancer

SillaJen executes definitive merger agreement to acquire Jennerex

Super cocktail of six natural compounds killed 100% of breast cancer cells without toxic side effects

Probe to measure immune function could lead to determine nanoparticle-based drugs for cancer patients

DNA-damaging drug and MK2 inhibitor combination could be effective against cancer

ESBC joins with Athena Breast Health Network to advance personalized breast cancer risk assessment

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in